Pharmaceutical Executive: June 2026

View the Pharmaceutical Executive June 2026 issue in an interactive format.

As the executive insights in our June issue illustrate, breakthroughs in pharma are rarely the result of a single discovery but are the product of organizations — and people — designed to keep moving forward.

Fresh off the HBA's Honorable Mentor award, Rick Winningham, CEO of Theravance Biopharma, reflects on a career defined by cultivating the cultures driving the science.

The driving force behind Lilly’s Medicine Foundry on transforming the discovery-to-production handoff.

China’s latest policy guidance sets new expectations for the pricing and reimbursement of novel drugs, and highlights the growing role of real-world evidence.

How emerging investment models are rewiring biotech funding structures for efforts in rare disease.

Special Guest Op-Ed: The time is now to elevate manufacturing and supply to a defining pillar of life sciences innovation.

AI-powered data analytics has evolved from a supporting function into the backbone of modern brand strategy and decision-making.

The framework’s key considerations for pharma brand managers.

Organizations must build a strong foundation that anchors AI deployments in critical areas.